Thermo Fisher Scientific, Inc.

TMO's RSI of 39.7 signals meaningful oversold conditions for a mega-cap trading at 25.5x earnings—notably reasonable for a biotech-adjacent compounder with consistent growth credentials. The stock sits comfortably below its 52-week high despite the sector's recent strength, suggesting either selective caution or legitimate valuation pullback after a strong run. With minimal short interest at 1.22% of float, there's no squeeze catalyst brewing, but the depressed momentum reading creates a technical setup that could attract value-oriented buyers if the company confirms growth durability. The valuation sits slightly elevated versus pure industrials yet appears justified given TMO's recurring revenue profile and defensive positioning across lab analytics and diagnostics.